Malignant neuroleptic syndrome associated with amisulpride;Malignes neuroleptisches syndrom durch amisulprid

Nervenarzt

Volumn 79, Issue 1, 2008, Pages 86-89

  Harter, C ^a   Obier, C ^a   Druschky, K F ^a   Eikelmann, B ^a  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Amisulpride; Malignant neuroleptic syndrome; Myopathy; Rhabdomyolysis; Second generation antipsychotics

Indexed keywords

AMISULPRIDE; CREATINE KINASE; LORAZEPAM; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; COMPARTMENT SYNDROME; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FEMALE; FEVER; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROLEPTIC MALIGNANT SYNDROME; OUTPATIENT; RHABDOMYOLYSIS; RIGOR; SURGICAL TECHNIQUE;

AFFECTIVE DISORDERS, PSYCHOTIC; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUSCLE, SKELETAL; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA, PARANOID; SULPIRIDE; VALPROIC ACID;

EID: 38349107655     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2343-8     Document Type: Article

References (18)

1. Altbasoglu EC, Ozguven HD, Saka MC, Goker C (2004) Rhabdomyolysis and coma associated with amislupride: A probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry 65: 1724-1725
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC
3. Ananth J, Parameswaran S, Gunatilake S et al. (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65: 464-470
4. Assion HJ, Heinemann F, Laux G (1998) Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 248: 231-239
5. Assion HJ, Volz HP (2004) Malignes neuroleptisches Syndrom. Thieme, Stuttgart New York
6. Baumgart U, Schmidt R, Spießl H (2005) Olanzapine-induced acute rhabdomyolysis. Pharamcopsychiatry 38: 36-37
7. Bertorini T (1997) Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrom and serotonin syndrome. Neurol Clin 15: 649-671
8. Bottlender R, Jäger M, Hofschuster E et al. (2002) Neuroleptic malignant syndrome due to atypical neuroleptics: Three episodes in one patient. Pharmacopsychiatry 35: 119-121
9. Davis JM, Janicak PG, Sakkas P et al. (1997) Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 7: 111-120
10. Deng MZ, Chen GQ, Philiphs MR (1990) Neuroleptic malignant syndrome in 12 of 9.792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry 147: 1149-1155
11. Gurrera RJ (1999) Sympathoadrenal hyperactivity and the etiology of neuroleptic syndrome. Am J Psychiatry 156: 169-180
12. Hatta K, Takahashi T, Nakamura H et al. (1998) Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. Eur Arch Psychiatry Clin Neurosci 248: 180-188
13. McElroy SL, Keck PE (1993) Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 38: 62-66
14. Meltzer HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity assoicated with antipsychotic drug treatment. Neuropsychopharmacology 15: 395-405
15. Northoff G (2002) Catatonia and neuroleptic malignant syndrom: psychopathology and pathophysiology. J Neural Transm 109: 1453-1467
16. Spivak B, Maline DI, Kozyrev VN et al. (2000) Frequency of neuroleptic malignant syndrom in a large psychiatric hospital in Moscow. Eur Psychiatry 15: 330-333
17. Viejo LF, Morales V, Punal P et al. (2003) Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 107: 45-49
18. Weller M, Kornhuber J (1992) Pathophysiologie und Therapie des Malignen Neuroleptischen Syndroms. Nervenarzt 63: 645-655